The Alzheimer’s Drugs Market is undergoing a fundamental shift as disease-modifying therapies redefine treatment objectives from symptom control to slowing disease progression. Between 2025 and 2031, the market is projected to expand from US$ 8.24 billion in 2024 to US$ 26.37 billion by 2031 , registering a strong CAGR of 13.6% . This growth is largely attributed to the increasing adoption of therapies targeting amyloid-beta and tau pathology, which are altering clinical practices and commercial strategies worldwide. Evolution of Treatment Paradigms Historically, Alzheimer’s treatment focused on managing cognitive and behavioral symptoms using cholinesterase inhibitors and NMDA receptor antagonists. While these therapies remain relevant, their inability to alter disease progression created an urgent need for more effective solutions. Disease-modifying therapies address this gap by targeting the biological mechanisms responsible for neuronal damage. Recen...